Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia

American Journal of Cardiology

Volumn 85, Issue 1, 2000, Pages 53-57

  Farnier, Michel ^a   Dejager, Sylvie ^b  

^a Point Medical   (France)

^b NOVARTIS PHARMA K K   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FENOFIBRATE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ATHEROGENESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

AGED; ALANINE TRANSAMINASE; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; ASPARTATE AMINOTRANSFERASES; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INDOLES; MALE; MIDDLE AGED; PROCETOFEN; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 0033985113     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00606-2     Document Type: Article

References (22)

1. Dujovne C.A. New lipid lowering drugs and new effects of old drugs. Curr Opin Lipidol. 8:1997;362-368.
2. Fruchart J.C., Brewer H.B., Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Am J Cardiol. 81:1998;912-917.
3. Prevention of coronary heart disease scientific background and new clinical guidelines. Recommendations of the European Atherosclerosis Society prepared by international task force for prevention of coronary heart disease . Nut Metab Cardiovasc Dis. 2:1992;113-156.
4. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation. 89:1994;1329-1445.
5. Brewer H.B. Comparative evaluation of fibric acid derivatives and HMG-CoA reductase inhibitors. Atherosclerosis. 97:1992;S11-S19.
6. Tikkanen M.J. Statins within-group comparisons, statin escape and combination therapy . Curr Opin Lipidol. 7:1996;385-388.
7. Pierce L.R., Wysowski D.K., Gross T.P. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA. 264:1990;71-75.
8. Marais G.E., Larson K.K. Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy. Ann Int Med. 112:1990;228-230.
9. Feher M.D., Foxton J., Banks D., Lant A.F., Wray R. Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolemia in patients with coronary artery disease. Br Heart J. 74:1995;14-17.
10. Athyros V.G., Papageorgiou A.A., Hatzikonstandinou H.A., Didangelos T.P., Carina M.V., Kranitsas D.F., Kontopoulos A.G. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol. 80:1997;608-613.
11. Ellen R.L.B., McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol. 81:1998;60B-65B.
12. Deslypere J.P. The role of HMG-CoA reductase inhibitors in the treatment of hyperlipidemia a review of fluvastatin . Curr Therap Res. 56:1995;111-128.
13. Langtry H.D., Markham A. Fluvastatin. A review of its use in lipid disorders. Drugs. 57:1999;583-606.
14. Leitersdorf E., Muratti E.N., Eliav O., Meiner V., Eisenberg S., Dann E.J., Sehayek E., Peters T.K., Stein Y. Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia comparative analysis with a fluvastatin-cholestyramine combination . Am J Med. 96:1994;401-407.
15. Eliav O., Schurr D., Pfister P., Friedlander Y., Leitersdorf E. High-dose fluvastatin and bezafibrate combination for heterozygous familial hypercholesterolemia. Am J Cardiol. 76:1995;76A-79A.
16. Balfour J.A., McTavish D., Heel R.C. Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs. 40:1990;260-290.
17. Farnier M., Bonnefous F., Debbas N., Irvine A. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia. Arch Intern Med. 154:1994;441-449.
18. Friedewald W.T., Levy R.I., Frederickson D.S. Estimation of concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
19. Shepherd J. Fibrates and statins in the treatment of hyperlipidemia an appraisal of their efficacy and safety . Eur Heart J. 16:1995;5-13.
20. Duell P., Connor W., Illingworth D.R. Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am J Cardiol. 81:1998;368-369.
21. Pogson G.W., Kindred L.H., Carper B.G. Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy. Am J Cardiol. 83:1999;1146.
22. Smit J.W.A., Jansen G.H., de Bruin T.W.A., Erkelens D.W. Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage. Am J Cardiol. 76:1995;126A-128A.